EGEGazette
Live
Houthis Accuse Saudi Arabia of 28 Airstrikes in 24 Hours; U.S. Intelligence Chief Visits CairoWashington Warns Citizens of Unexpected Escalation in Middle EastIran Says Strait of Hormuz Will Stay Closed Until US Meets Its ConditionsTrump faces dual setback as U.S. courts block voting and immigration restrictionsLawsuit Filed Against Trump and His Company Over Paid Early Access Service to His PostsTrump Renews Bid to Restrict Birthright Citizenship Through Curbing "Birth Tourism"Trump Cuts Camp David Vacation Short Amid Middle East Escalation WarningsReporters From CNN, MS NOW and Politico Denied White House Access After Trump BanFederal Immigration Agent Shoots and Injures Man in Austin, TexasPowerful Explosions Reported in Syria's Aleppo CountrysideSix Pakistani soldiers, including two officers, killed in clash near Afghan borderCalls to Withdraw Secret Military Plan in Saxony-Anhalt Amid Fears of Leaks to Russia
businessReported

Novo Nordisk Rebrands to 'Novo,' CEO Says Obesity Strategy Needs Rethink

In an interview with CNBC, new chief executive Mike Doustdar said the Danish drugmaker's rebranding marks a new chapter as it faces intensifying competition from Eli Lilly.

· 1 min read · language: en

Novo Nordisk is rebranding itself as "Novo," according to an interview its chief executive, Mike Doustdar, gave to CNBC, which reported the change alongside his comments on the company's competitive position in the obesity-drug market.

Doustdar told CNBC that the rebranding represents "the beginning of a new chapter" for the Danish pharmaceutical company, which has built its recent growth around demand for its weight-loss and diabetes treatments.

According to CNBC, the drugmaker is reassessing its approach to the obesity market as it faces stiff competition from U.S. rival Eli Lilly, a company that has emerged as a major challenger in the same segment.

The CNBC report did not provide further detail on the specific elements of the rebranding or the timeline for implementing changes to the company's obesity strategy.

CNBC's report is based on its interview with Doustdar; Novo Nordisk has not issued a separate public statement covering the same details, according to the available reporting.

Sources

EGazette summarizes reporting from multiple sources; follow the links for the originals.

Related articles

Comments

Sign in to join the conversation.

Forgot password?

No account?

Loading comments…